AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Synopsis: Current rofecoxib use was associated with a higher risk of acute myocardial infarction or admission for heart failure compared to celecoxib.
Sources: Soloman DH, et al. Circulation. 2004;109: 2068-2073; Mamdani M, et al. Lancet. 2004;363: 1751-1756.
**********
CYCLOOXYGENASE-2 INHIBITORS ARE ASSOCIATED with less gastrointestinal bleeding than nonselective non-steroidal anti-inflammatory drugs (NSAIDs), but concern about their cardiovascular effects have arisen. Thus, Solomon and colleagues conducted a case controlled study of 54,475 patients older than 65-years-old identified in a state-sponsored pharmaceutical benefits program for elderly or disabled low-income individuals from 1998-2000. Patients with diseases that may have obscured the relationship between COX-2 drags and cardiovascular disease were excluded. The case defining event was hospitalization for acute myocardial infarction (AMI), determined by chart review, which was found in 10,895. For each AMI, 4 controls were found and matched for age and sex. Logistic regression analyses…
Source: HighBeam Research, COX-2 inhibitor controversy.(Abstracts & Commentary)